Company SalvaRx Group plc

Equities

SALV

IM00BZ4SS228

Biotechnology & Medical Research

Business Summary

Managers

Members of the board

Share class

Company contact information

Sector

Sector Bio Therapeutic Drugs

Delayed London S.E. Other stock markets			5-day change	1st Jan Change
- ^GBX	-.--%		-47.06%	-.--%

2019	SalvaRx Evaluates Takeover Opportunities	CI
2019	Salvarx Group plc Reports Earnings Results for the Half Year Ended June 30, 2019	CI

- SalvaRx Group Plc is a Isle of Man-based company. The Company engaged in drug discovery and development, focused on immune oncology. The Company invests in novel cancer immuno-therapies and provides its portfolio companies with operational support ranging from direct operation of subsidiaries to advisory or part-time involvement in more established companies.

Managers	Title	Age	Since
Denham Eke DFI	Director of Finance/CFO	73	08/19/08

Members of the board	Title	Age	Since
Jim Mellon CHM	Chairman	68	-
Peter Redmond BRD	Director/Board Member	76	-
Gregory Bailey FOU	Founder	68	01/07/01
Denham Eke DFI	Director of Finance/CFO	73	08/19/08

	Vote	Quantity	Free-Float	Company-owned shares	Total Float
Stock A	1	36,699,642	7,460,186 ( 20.33 %)	0	20.33 %

SalvaRx Group Plc

Commerce House 1 Bowring Road

IM8 2LQ, Ramsey

http://www.salvarx.io/

Healthcare

Pharmaceuticals & Medical Research

Biotechnology & Medical Research

Biotechnology & Medical Research

Bio Therapeutic Drugs

	1st Jan change	Capi.
SALVARX GROUP PLC	-.--%	2.16M
VERTEX PHARMACEUTICALS INCORPORATED	+20.63%	126B
ARGENX SE	+24.16%	27.95B
BIONTECH SE	-20.17%	20.5B
GENMAB A/S	-16.06%	17.12B
BEIGENE, LTD.	-18.07%	16.1B
WUXI APPTEC CO., LTD.	-47.70%	14.97B
NEUROCRINE BIOSCIENCES, INC.	+11.92%	14.84B
SAREPTA THERAPEUTICS, INC.	+58.32%	14.38B
INSMED INCORPORATED	+149.98%	12.37B

Bio Therapeutic Drugs